Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at molecular markers and genetic markers in patients undergoing radiation therapy for cancer.
| Condition |
|---|
|
Malignant Tumor of Lymphoid Hemopoietic and Related Tissue Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Retrospective |
| Official Title: | Molecular and Genetic Markers in the Local-regional Management of Patients Undergoing Radiation Therapy |
| Estimated Enrollment: | 0 |
| Study Start Date: | May 2006 |
| Primary Completion Date: | May 2006 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
- Determine local-regional control in patients undergoing radiation therapy for cancer, as a function of expression of specific molecular/genetic markers.
Secondary
- Determine complications of radiation therapy for patients undergoing radiation therapy for cancer.
OUTLINE: Previously collected tissue samples are analyzed using immunohistochemical staining and other molecular/genetic study methods to detect markers, including p53, cyclin D1, HER-2-neu, bcl-2/BAX, and EGFR. Patient charts are also reviewed with emphasis on local-regional relapse.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
All patients undergoing radiation therapy for malignant disease will be eligible for these studies. Initially we will focus on specific disease sites, such as breast, prostate and lung, but ultimately we will expand this to include any disease site. Patients who met standard criteria for radiation therapy but ultimately did not receive radiation therapy will be used as a control arm if needed.
DISEASE CHARACTERISTICS:
- Diagnosis of cancer
- Undergoing radiation therapy for malignant disease
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations| United States, New Jersey | |
| Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School | |
| New Brunswick, New Jersey, United States, 08903 | |
| Principal Investigator: | Bruce G. Haffty, MD | Cancer Institute of New Jersey |
More Information
Additional Information:
No publications provided
| Responsible Party: | Bruce Haffty, MD, Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School |
| ClinicalTrials.gov Identifier: | NCT00899808 History of Changes |
| Other Study ID Numbers: | CDR0000592887, P30CA072720, CINJ-000609, CINJ-IRB-0220060141 |
| Study First Received: | May 9, 2009 |
| Last Updated: | March 17, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Medicine and Dentistry New Jersey:
|
unspecified adult solid tumor, protocol specific unspecified childhood solid tumor, protocol specific hematopoietic/lymphoid cancer |
Additional relevant MeSH terms:
|
Neoplasms |
ClinicalTrials.gov processed this record on May 16, 2013